ATAGI advised Australian travellers who received the Abhayrab vaccine in India after November 1, 2023, to restart immunisation due to counterfeit concerns. The manufacturer, IIL, clarified that the issue involves a specific batch and urged ATAGI to reconsider its advisory to avoid public anxiety.